Singapore backs vutrisiran with major subsidy
2026-09-01
Government money is finally catching up with RNA interference. In Singapore, vutrisiran for transthyretin amyloidosis will enter the subsidy list, with eligible patients able to receive support covering as much as three quarters of the treatment bill, making the city‑state the first in ASEAN to underwrite this specific therapy.
That status matters because transthyretin amyloidosis is rare, progressive, and expensive to treat, and payers usually retreat from orphan drugs once they see the price tags and the chronic nature of care, yet Singapore is choosing to anchor vutrisiran inside its public financing architecture, turning a high‑cost RNAi agent into a partially socialised benefit instead of a luxury product for a handful of self‑funded patients.
Behind the move sits a hard medical logic: vutrisiran targets transthyretin at the level of hepatic protein synthesis, lowering pathogenic amyloid formation rather than only managing neuropathic or cardiomyopathic symptoms, and by absorbing up to 75% of the cost the state is betting that earlier disease modification will offset downstream spending on hospitalisations, assistive devices and end‑stage complications, while sending a clear signal that advanced genetic therapies can secure a place in mainstream reimbursement.
Loading...
